Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II clinical trial of CTM-N2D

Next Previous
Trial Profile

A phase II clinical trial of CTM-N2D

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Apr 2025 According to a CytoMed Therapeutics media release, SunAct Cancer Institute received approval from Vedant Hospital Institutional Ethics Committee to conduct a Phase II Investigator Initiated Trial for various cancer indications. The trial was subsequently registered with the Clinical Trials Registry - India in March 2025. The first patient recruitment expected to commence in the second half of 2025. This clinical trial in Mumbai will be funded through the Company's internal resources.
  • 28 Apr 2025 Status changed from planning to not yet recruiting, according to a CytoMed Therapeutics media release.
  • 06 Jan 2025 According to a CytoMed Therapeutics media release, company announced that it has entered into a Business & Research Collaboration Agreement (BRCA) with Mumbai-based SunAct Cancer Institute Private Limited (SunAct), a company incorporated in the Republic of India (India).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top